The circadian clock regulates osteoblast gene expression, but whether it also times the post‑translational modification of osteocalcin remains unknown. We hypothesize that the vitamin K cycle enzymes GGCX and VKORC1 are under direct circadian control in bone, and that loss of this timing drives the rise in undercarboxylated osteocalcin (ucOC) seen with aging, independent of dietary vitamin K availability.

Core mechanistic reasoning: Vitamin K recycling depends on the redox‑sensitive VKORC1 enzyme, which reduces vitamin K epoxide back to its active hydroquinone form. Cellular NAD+/NADH ratios and reactive oxygen species (ROS) oscillate with the circadian rhythm, influencing VKORC1 activity through reversible cysteine oxidation. In osteoblasts, BMAL1:CLOCK heterodimers could bind E‑box elements in the promoters of Ggcx and Vkorc1, driving peak transcription during the active phase. Concurrently, circadian fluctuations in hepatic vitamin K supply and local bone microenvironment pH would create a temporal window where γ‑carboxylation is maximally efficient. When circadian rhythms flatten—due to shift work, aging, or genetic clock loss—this gating is blunted, causing a mismatch between enzyme availability and substrate flux. The result is chronic undercarboxylation of osteocalcin, reduced Gla‑OC binding to hydroxyapatite, and dysregulated mineral crystal growth.

This hypothesis generates several falsifiable predictions: (1) In wild‑type mouse calvarial osteoblasts, Ggcx and Vkorc1 mRNA and protein will show ~24‑hour expression peaks that are abolished in Bmal1‑null cells. (2) Chromatin immunoprecipitation will reveal BMAL1 binding to conserved E‑boxes in the Ggcx and Vkorc1 promoters. (3) Pharmacological restoration of circadian amplitude (e.g., via timed nobiletin dosing) will rescue ucOC levels in aged mice without altering serum vitamin K. (4) Human bone biopsies from older donors with flattened cortisol rhythms will exhibit lower GGCX/VKORC1 protein and higher ucOC/total OC ratios compared with age‑matched donors with robust rhythms, even after adjusting for vitamin K intake.

Experimental approach: Primary osteoblasts isolated from PER2::LUC reporter mice will be synchronized with dexamethasone shock. Bioluminescence will monitor clock phase while qPCR and Western blot track Ggcx/Vkorc1 across cycles. CRISPR‑mediated deletion of predicted E‑boxes will test necessity of direct clock regulation. Carboxylation status will be assessed by mass spectrometry‑based detection of Gla residues on osteocalcin secreted into culture media. In vivo, C57BL/6 mice subjected to chronic jet‑lag will undergo longitudinal micro‑CT and serum ucOC measurements; interventions with timed vitamin K2 supplementation or NAD+ boosters will determine whether re‑synchronizing the vitamin K cycle mitigates bone loss.

If validated, this model positions the circadian vitamin K cycle as a actionable node connecting clock integrity to bone quality. It shifts focus from merely correcting vitamin K deficiency to restoring temporal enzymatic competence, offering a novel geroprotective strategy for age‑related osteoporosis.